Show simple item record

dc.contributor.authorRodríguez Sojo, María Jesús
dc.contributor.authorRuiz Malagón, Antonio Jesús 
dc.contributor.authorRodríguez Cabezas, María Elena 
dc.contributor.authorGálvez Peralta, Julio Juan 
dc.contributor.authorRodríguez Nogales, Alba
dc.identifier.citationRodríguez-Sojo, M.J.; Ruiz-Malagón, A.J.; Rodríguez-Cabezas, M.E.; Gálvez, J.; Rodríguez-Nogales, A. Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights. Nutrients 2021, 13, 1016. []es_ES
dc.descriptionThis work was supported by the Junta de Andalucía (CTS 164) and Instituto de Salud Carlos III (PI19/01058) with funds from the European Union.es_ES
dc.descriptionM.J. Rodríguez-Sojo is a predoctoral fellow from University of Granada (“Programa de Doctorado en Biomedicina”); A.J. Ruiz-Malagón is a predoctoral fellow from Formación de Profesorado Universitario Program (“Programa de Doctorado en Medicina Clínica y Salud Pública”), and A. Rodríguez-Nogales is a postdoctoral fellow of Instituto de Salud Carlos III (Miguel Servet Program).es_ES
dc.description.abstractProbiotics microorganisms exert their health-associated activities through some of the following general actions: competitive exclusion, enhancement of intestinal barrier function, production of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it has been described to possess potential beneficial effects on inflammatory processes and immunological alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory and immunomodulatory properties and elucidated the precise mechanisms of action involved in its beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on host health, mechanisms, and future therapeutic approaches.es_ES
dc.description.sponsorshipJunta de Andalucia CTS 164es_ES
dc.description.sponsorshipInstituto de Salud Carlos III European Commission PI19/01058es_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.rightsAtribución 3.0 España*
dc.subjectLimosilactobacillus fermentum CECT5716es_ES
dc.subjectMechanism of actiones_ES
dc.subjectGastrointestinal diseaseses_ES
dc.titleLimosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insightses_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España